Clinical Trial Update: Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant tislelizumab plus chemotherapy for initially unresectable stage IIIA/N2 non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING